E.Linezolid is the right answer
) Congrat
aktorque,doctorsmonsters
It's quite hard. Actually I got wrong ans when I first confront this problem in Pretest Pharmacology(Marshal Shlafer)
Linezolid
Therapeutic Uses
Linezolid is FDA approved for treatment of infections caused by
- vancomycin-resistant E. faecium
-
nosocomial pneumonia caused by methicillin-susceptible and-resistant strains of S. aureus
-
community-acquired pneumonia caused by penicillin-susceptible strains of S. pneumoniae
-
complicated skin and skin-structure infections caused by streptococci and methicillin-susceptible and -resistant strains of S. aureus
-
uncomplicated skin and skin-structure infections
Untoward Effects
The drug seems to be well tolerated, with generally minor side effects (
e.g., gastrointestinal complaints, headache, rash).
Myelosuppression, including anemia, leukopenia, pancytopenia, and thrombocytopenia, has been reported in patients receiving linezolid. Thrombocytopenia or a significant reduction in platelet count has been associated with linezolid in 2.4% of treated patients, and its occurrence is related to duration of therapy. Platelet counts should be monitored in patients with risk of bleeding, preexisting thrombocytopenia, or intrinsic or acquired disorders of platelet function (including those potentially caused by concomitant medication) and in patients receiving courses of therapy lasting beyond 2 weeks.
Linezolid is a weak, nonspecific inhibitor of monoamine oxidase. Patients receiving concomitant therapy with an adrenergic or serotonergic agent or consuming more than 100 mg of tyramine a day may experience palpitations, headache, or hypertensive crisis. Peripheral and optic neuropathy, which seem to be reversible upon drug discontinuation, have been reported with prolonged use. Linezolid is neither a substrate nor an inhibitor of CYPs.
